<DOC>
	<DOCNO>NCT00476008</DOCNO>
	<brief_summary>The purpose study determine whether memantine delay progression drive impairment patient mild Alzheimer 's Disease ( AD ) .</brief_summary>
	<brief_title>Delaying Progression Driving Impairment Individuals With Mild Alzheimer 's Disease</brief_title>
	<detailed_description>It well know , great concern patient family , individual Alzheimer 's disease ( AD ) eventually become driving impaired . Drivers dementia estimate 2-8 time likely involved automobile crash unimpaired peer . Approximately half individual mild AD skill need drive safely . Formal driver evaluation may necessary make distinction . Some reviews literature suggest individual identify high risk , AD , advise physician cease drive altogether . Other study suggest individual may continue drive 4 year follow diagnosis . Memantine may effective delay progression drive impairment individual mild AD . If investigator demonstrate significant delay decline drive ability , could extend drive time therefore immense benefit patient caregiver . Comparison ( ) : Subjects treat memantine period 12 month , compare subject placebo .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Men woman age 60 year age old Subjects must either previously diagnose mild Alzheimer 's Disease ( AD ) neurologist , psychiatrist , geriatrician , evaluated Memory Disorders Center prior entry study Subjects must score â‰¥ 23 MiniMental State Examination ( MMSE ) Screening Visit Subjects must receive pass score DriveABLE test Female subject must least 2 year postmenopausal surgically sterile Written inform consent must obtain subject prior initiation study specific procedure Subjects treat depot neuroleptic within six ( 6 ) month Screening Visit Subjects fail OPTEC vision test screen visit Subjects score &gt; 7 Hachinski Test screen visit Subjects evidence clinically significant active pulmonary , gastrointestinal , renal , hepatic , endocrine cardiovascular system disease ( subject control hypertension , right bundle branch block [ complete partial ] pacemaker may include study ) . Subjects thyroid disease may also include study , provide euthyroid treatment . Subjects control diabetes may also include Recent ( &lt; 2years ) B12 folate deficiency consider clinically significant Subjects evidence psychiatric/neurologic disorder include , limited , stroke , Vascular Dementia , LewyBody Disease , Parkinson 's Disease , seizure disorder , head injury loss consciousness within past 5 year , psychotic disorder , bipolar disorder Subjects taking , take , amantadine , ketamine , dextromethorphan discontinue switched allowable alternative medication prior minimum allowable interval Baseline Subjects investigational drug study receive treatment investigational drug within 30 day ( 5 halflives , whichever long ) Screening Visit Any condition , would make subject , opinion investigator , unsuitable study If subject take Acetylcholinesterase inhibitor ( AChEls ) , must stable dose &gt; 3 month prior baseline . No initiation AChEls permit ; discontinuation dose reduction permit</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Mild Alzheimer 's Disease</keyword>
	<keyword>Driving</keyword>
	<keyword>Driving Impairment</keyword>
</DOC>